Overview

LEO 90100 in the Treatment of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
LEO Pharma
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcipotriene
Calcitriol